DEBIOPHARM-DEBIO0123-102
Phase I
OPEN TO ACCRUAL *
A Phase 1, Dose-Finding Study of Debio 0123 as Monotherapy in Adult Patients with Advanced Solid Tumors, Followed by an Expansion Part to Assess Safety and Preliminary Anti-Tumor Activity